Board of Directors
Amplia Therapeutics is governed by a small board which works closely with the company's executive team, together with external consultants and collaborators, to achieve maximum value for the company's stakeholders.
Warwick Tong MB ChB MPP GAICD
Non-Executive Chairman of the Board
Warwick is a NZ trained physician with more than 25 years’ experience in the Pharmaceutical and Biotechnology industry.
After his early career in General Medical Practice Warwick has held a wide variety of roles in the pharmaceutical and biotech industry in NZ(Glaxo) Singapore (GlaxoWellcome) London (GSK), Boston (Surface Logix) and Melbourne (CTx - Cancer Therapeutics CRC). His roles have included; Medical Director, Regional Business Development Director (Asia Pacific), Commercial Strategy Director (International) and SVP Development (USA).
He was CEO and Director of CTx from 2011 until April 2018 and remains in an advisory role and as Director and Chair of the CTx commercialisation company, CTxONE. He is a Director and Chair of BioMedVic, a member of the Governance Board of the ARC CoE in Convergent Bio Nano Science, a member of the SAB of the Maurice Wilkins Centre in Auckland NZ, the Advisory Board of Cortex Health, Melbourne, the Industry Advisory Board, School of Biomedical Sciences, University of Melbourne and a member of the CSIRO Manufacturing, Business Advisory Committee.
Warwick was educated at the University of Auckland and Victoria University, Wellington, New Zealand and is a Graduate of the Australian Institute of Company Directors.
Dr. Tong was appointed as a Non-Executive Director on the 4th of May 2018 and Chairman on 25 May 2018. Dr. Tong is also a member of the Audit Committee.
John Lambert PhD GAICD
Chief Executive Officer and Managing Director
John has more than 16 years of drug discovery and development experience. His appointments include leadership roles in Drug Development, Operations Management and Drug Discovery (Biota Pharmaceuticals), as Senior Director (Medicines Development for Global Health) and as an academic researcher in medicinal and biological chemistry (University of Melbourne, ANU and Harvard University).
He is an experienced manager of both in early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products. As such, his experience spans the entire spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.
John joined Amplia Therapeutics as Operations Manager in August 2018 and was appointed as CEO on 24 June 2019 and Managing Director on 6 February 2020.
Robert Peach Ph.D
Independent Non-Executive Director
Dr Peach has over 25 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry. In 2009 he co-founded Receptos, becoming Chief Scientific Officer and raising $59M in venture capital and $800M in an IPO and three subsequent follow-on offerings. In August 2015 Receptos was acquired by Celgene for $7.8B. Robert held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments. His extensive drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs. He is currently on the Board of Directors and Scientific Advisory Board of Avalia Immunotherapies and is a consultant for several other biotechnology companies.
Robert is the co-author of 70 scientific publications and book chapters, and 17 patents. He was educated at the University of Canterbury and the University of Otago, New Zealand.
Dr. Peach was appointed as an independent Non-Executive Director on the 2nd of September 2015 and is a member of the Remuneration Committee.
Christopher Burns B.Sc. (Hons) PhD GAICD
Chris is an experienced drug discovery leader having worked in various roles in pharma, biotech and academia for 25 years.
After completing a Ph D in Organic Chemistry at the University of Melbourne Chris undertook postodoctoral studies in the USA before moving to Pfizer UK, where he worked on a variety of drug discovery projects. After 5 years he returned to Australia as a Research Fellow at the University of Sydney with the CRC for Molecular Engineering and Technology and after two years moved to the biotechnology company Ambri as Head of Chemistry.
Chris then moved to the Melbourne-based biotech Cytopia as Head of Medicinal Chemistry and later as Research Director. Over this time he led teams in the discovery of two anti-cancer agents that have entered clinical trial, including the drug momelotinib which successfully completed Phase III studies. Most recently Chris was a Laboratory Head at the Walter and Eliza Hall Institute of Medical Research in Melbourne and currently holds executive roles with privately held biotechs MecRx, Certa Therapeutices and OccuRx.
Dr Burns is the inventor on over 30 patents and a co-author on over 50 scientific publications and is a fellow of the Royal Society of Chemistry (UK) and the Royal Australian Chemical Institute.
Dr. Burns was appointed as a Non-Executive Director on the 4th of May 2018 and is a member of the Remuneration Committee.